Spectrum Pharmaceuticals (NASDAQ:SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, yesterday announced that its pivotal trial of Captisol-enabled™ (propylene glycol-free) Melphalan met its primary end points. Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) shares after opening at $7.25 moved to $7.56 on last trade day and at the end of the day closed at $7.18. Company price to sales ratio in past twelve months was calculated as 3.01 and price to cash ratio as 2.93. Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) showed a positive weekly performance of 7.16%.
MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering and identifying innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, announced the presentation of pre-clinical data demonstrating that MGD007, a dual-affinity re-targeting (DART(R)) protein, has potent activity against colorectal cancer cells both in vitro and in vivo. MacroGenics Inc. (NASDAQ:MGNX) shares advanced 7.50% in last trading session and ended the day on $20.65. MGNX return on equity ratio is recorded as -32.80% and its return on assets is -5.50%.
Actinium Pharmaceuticals Inc. (NYSEMKT:ATNM) a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers announces the availability of an exclusive interview with its President and CEO Kaushik J. Dave Ph.D. Actinium Pharmaceuticals Inc. (NYSEMKT:ATNM) shares moved up 4.45% in last trading session and was closed at $13.15, while trading in range of $12.25 – $13.45. Actinium Pharmaceuticals Inc. (NYSEMKT:ATNM) year to date (YTD) performance is 123.26%.
Israel-based Evogene Ltd. (NYSE:EVGN) has released its 2013 financial results, signed an agreement for the commercial production of castor beans in Brazil and announced enhanced capabilities for gene stacking prediction with the introduction of PlaNet (Plant Networks) version 2.0 computational platform. Evogene Ltd (NYSE:EVGN) weekly performance is -0.06%. On last trading day company shares ended up $17.70. Evogene Ltd (NYSE:EVGN) distance from 50-day simple moving average (SMA50) is -6.46%. Analysts mean target price for the company is $23.75.